Related Experiment Videos
Visual field defects with vigabatrin: epidemiology and therapeutic implications
1University Hospital of Kuopio and University of Kuopio, Finland. reetta.kalviainen@kuh.fi
CNS Drugs
|July 21, 2001
Summary
Vigabatrin, an antiepileptic drug, can cause persistent visual field constriction in 31% of adult patients. This risk increases with male gender and cumulative dosage, necessitating regular visual field monitoring.
Area of Science:
- Neurology
- Ophthalmology
- Pharmacology
Background:
- Vigabatrin is an antiepileptic drug (AED) that inhibits gamma-aminobutyric acid (GABA) transaminase.
- Previous reports indicated visual field constriction associated with vigabatrin, but causality was debated.
Purpose of the Study:
- To establish the causal relationship between vigabatrin and visual field defects.
- To determine the prevalence and risk factors of vigabatrin-associated visual field constriction.
Main Methods:
- A Marketing Authorisation Holders survey of 335 adult vigabatrin recipients.
- Comparison with an unexposed control group.
- Analysis of existing studies on vigabatrin-treated patients.
Main Results:
- 31% of adult patients treated with vigabatrin experienced visual field defects.
- Male gender approximately doubles the risk of visual field loss.
- Defects typically manifest as bilateral concentric visual field constriction, worsening with cumulative dose and treatment duration.
Conclusions:
- Vigabatrin treatment is causally linked to bilateral concentric visual field constriction.
- Regular visual field testing is crucial for patients on vigabatrin.
- Vigabatrin should be reserved for resistant epilepsy cases unresponsive to other AEDs, with careful risk-benefit assessment.